Paper Details

  1. Home
  2. Paper Details

Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial.

Author: BuddG T, BukowskiR M, GanapathiR, MidhaK K, MillerR L, PurvisJ, ShepardK, WeickJ K

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The combination of trifluoperazine and doxorubicin was well-tolerated in patients with doxorubicin resistance. Trifluoperazine did not affect doxorubicin toxicity but may enhance its efficacy, especially in patients with acquired resistance.
Paper Details　
Original Abstract of the Article :
Drug resistance to chemotherapy agents such as doxorubicin appears to be an important cause of therapeutic failure in cancer treatment. Based on preclinical information demonstrating that the phenothiazine calmodulin-inhibitor trifluoperazine can enhance retention and cytotoxicity of doxorubicin in ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.1988.6.5.880

データ提供：米国国立医学図書館（NLM）

Overcoming Doxorubicin Resistance: A Phase I/II Trial of Trifluoperazine

This study explores the potential of trifluoperazine, a calmodulin-inhibitor, to enhance the effectiveness of doxorubicin, a chemotherapy drug, in treating cancer. The authors conducted a phase I/II clinical trial to determine the maximum tolerated dose of trifluoperazine when combined with doxorubicin. Their findings suggest that the combination is well tolerated and may offer a potential strategy to overcome doxorubicin resistance in some patients.

Navigating the Desert of Drug Resistance: A New Approach to Cancer Treatment

This study addresses the challenge of drug resistance in cancer treatment, focusing on the potential of trifluoperazine to enhance the effectiveness of doxorubicin. Imagine the desert of drug resistance, where conventional therapies often fail to reach their target. This study seeks a new oasis of treatment strategies, exploring the potential of trifluoperazine to overcome this formidable challenge.

The Oasis of Combination Therapy: A New Path to Overcoming Resistance

This research offers a potential solution for overcoming doxorubicin resistance in cancer treatment. The authors' findings suggest that combining trifluoperazine with doxorubicin may enhance the effectiveness of this chemotherapy drug. It's like discovering a hidden oasis in the desert of drug resistance, offering a new path to overcome this formidable challenge.

Dr.Camel's Conclusion

This study explores a novel approach to combating drug resistance in cancer treatment, using a combination of trifluoperazine and doxorubicin. It's like finding a new oasis in the vast desert of drug resistance, offering a potential pathway to more effective therapies.

Date :
  1. Date Completed 1988-06-10
  2. Date Revised 2017-02-10
Further Info :

Pubmed ID

3367191

DOI: Digital Object Identifier

10.1200/JCO.1988.6.5.880

Related Literature

Article Analysis
・Side Effects of trifluoperazine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.